Mass azithromycin for prevention of child mortality among children with acute malnutrition: A subgroup analysis of a cluster randomized controlled trial.


Journal

PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676

Informations de publication

Date de publication:
2024
Historique:
received: 02 02 2024
accepted: 30 09 2024
medline: 28 10 2024
pubmed: 28 10 2024
entrez: 28 10 2024
Statut: epublish

Résumé

Children with acute malnutrition are at high risk of morality. Mass azithromycin distribution reduces all-cause mortality among children aged 1-59 months, and effects may be greater in underweight infants. Here, we evaluate the efficacy of azithromycin for reducing all-cause mortality in children aged 6-59 months with acute malnutrition (mid-upper arm circumference, MUAC, < 12.5 cm). Communities in Nouna District, Burkina Faso were 1:1 randomized to biannual mass distribution of single dose azithromycin or placebo to all children aged 1-59 months. Mortality was assessed during each census and treatment round. MUAC measurements were collected for all children. We evaluated the effect of azithromycin on mortality in subgroups of children aged 6-59 months defined by acute malnutrition (MUAC < 12.5 cm versus MUAC ≥ 12.5 cm). In children with MUAC < 12.5 cm, mortality rates were 51% lower among those living in azithromycin communities compared to placebo (incidence rate ratio 0.49, 95% confidence interval, CI, 0.25 to 0.99; incidence rate difference -18.1 deaths per 1,000 person-years, 95% CI -37.0 to -0.01), which was greater than the reduction in mortality among children with MUAC ≥ 12.5 cm (P-value for interaction on the relative scale = 0.09; P-value for interaction of the additive scale = 0.03). Children with acute malnutrition may benefit from single dose azithromycin above and beyond those without acute malnutrition. Trial registration: ClinicalTrials.gov NCT03676764; https://clinicaltrials.gov/study/NCT03676764.

Identifiants

pubmed: 39466816
doi: 10.1371/journal.pgph.0003875
pii: PGPH-D-24-00144
doi:

Banques de données

ClinicalTrials.gov
['NCT03676764']

Types de publication

Journal Article

Langues

eng

Pagination

e0003875

Informations de copyright

Copyright: © 2024 Sié et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Ali Sié (A)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California, United States of America.
Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America.

Mamadou Ouattara (M)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Mamadou Bountogo (M)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Valentin Boudo (V)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Thierry Ouedraogo (T)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Clarisse Dah (C)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Guillaume Compaoré (G)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Elodie Lebas (E)

Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California, United States of America.

Huiyu Hu (H)

Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California, United States of America.

Travis C Porco (TC)

Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California, United States of America.

Benjamin F Arnold (BF)

Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California, United States of America.
Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America.
Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States of America.

Kieran S O'Brien (KS)

Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California, United States of America.
Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America.
Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States of America.
Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.

Thomas M Lietman (TM)

Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California, United States of America.
Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America.
Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States of America.
Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.

Catherine E Oldenburg (CE)

Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California, United States of America.
Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America.
Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States of America.
Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.

Classifications MeSH